Ionis Pharmaceuticals suffered an 8.6% stock decline after its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events. Despite the setback, an analyst from Canaccord Genuity maintained a bullish $85 price target for the company.